| |
The CAT’s technology development initiative
focuses on the discovery and development of technologies most likely to
impact the New York State economy. Particular emphasis is placed on the
development of platform technologies that have the potential to lead to
new company formation.
The Center provides a variety of “value added” services including:
- Commercial assessment of the technology,
- Development of critical path management strategies,
- Financial investment to accomplish technical goals,
- Hands-on technical support utilizing the Center’s Applied Bioscience
Laboratory and/or Custom DNA Microarray Facility,
- Introduction to potential industry or academic collaborators,
- Exploration of external financing opportunities.
Eight technologies related to, or directly supported by the CAT, have
been the foundation for new company formation in New York State.
AcousticScan Inc., established in 2001,
is focused on the commercialization of high performance bone imaging technologies
for the early diagnosis and monitoring of treatment of osteoporosis, delayed
fracture unions, and other musculoskeletal disorders. The Company is developing
a proprietary Scanning Confocal Acoustic Navigation (SCAN) System that
is capable of non-invasive, high resolution, image-based determination
of the material properties of bone.
Brook Biotechnologies was created in
1994 to develop and commercialize the first FDA-approved diagnostic test
kit for Lyme Disease. Brook Biotechnologies has recently ceased operations
and the technology has been licensed Baxter Diagnostics.
Clear Solutions Biotech, Inc.®,
was launched in November 1994 to commercialize a family of patented technologies
developed by the CAT for the derivitization of Hyaluronic Acid (HA) and
other natural or synthetic polymers. Clear Solutions Biotech is part of
The Collaborative Group of companies.
Cornerstone Pharmaceuticals, formed
in 2000, is developing novel anti-cancer drug delivery technology and
unique anti-cancer agents for the treatment of diverse cancers. Individually
and in combination, the Company’s unique Emulsiphan technology and
AEM compounds are expected to represent a radical advancement in cancer
treatment. The company is about to enter human clinical trials with its
first product.
Ortek Therapeutics, founded in 1998,
is a fully integrated specialty pharmaceutical company engaged in developing
and commercializing proprietary products for the treatment of dental disorders.
Ortek currently sells ProClude® desensitizing prophylaxis paste. In
addition, the company is developing additional products for dentinal sensitivity
and new therapies for tooth decay, drug resistant infections and cancer.
All technologies are exclusively licensed by the Company from the Research
Foundation of SUNY, and developed in the Department of Oral Biology and
Pathology at Stony Brook University.
Stony Brook Technology & Applied Research,
Inc. (STAR), founded in 2002, is a development stage, tissue engineering
company that is developing novel scaffolding materials with wide applicability
in tissue regeneration. The initial focus of the company is on the development
of an effective means of delivering cells for augmenting bone regeneration.
Viatronix, founded in 1999, is a company
with breakthrough software technology in the field of medical diagnostics.
The company’s V3D technology platform uses state-of-the-art, computer-based,
three dimensional (3-D) volumetric rendering to display a patient's anatomy
as a virtual computer model. This virtual model, displayed on a computer
screen, offers a trained V3D user an accurate, non-invasive method for
detecting anomalies such as colon polyps, calcified plaque build up or
aortic aneurysms.
Vitatex, established in 2001, is developing
therapies that battle cancer cells without the side effects normally associated
with existing treatments. The company has developed monoclonal antibodies
that inhibit specific protein digesting enzymes and stop tumors from developing
new blood vessels. Vitatex scientists are now using this science to explore
novel antiangiogenesis therapies that can restrict tumor growth.
back to top
|
|
